Key result
Cerebral embolic protection devices and tailored antithrombotic strategies have not yet demonstrated a definitive reduction in periprocedural stroke rates for patients undergoing transcatheter aortic valve implantation.
Why the study?
Cerebrovascular events remain a serious complication in TAVI, and with expansion to younger low-risk patients, clear clinical benefits of cerebral embolic protection devices have not been demonstrated in randomized trials.
Stroke prevention during TAVI requires a multifactorial approach including procedural and periprocedural strategies, as cerebral embolic protection devices have not yet shown a definitive clinical benefit in randomized trials.
No takes yet. Share an insight, caveat, or question.
Embolic protection and tailored antithrombotics lack proven TAVI stroke benefit; leaves open need for effective multifactorial prevention strategies.
Linder et al. (2022) conducted a review in Aortic stenosis undergoing Transcatheter Aortic Valve Implantation (TAVI). Periprocedural stroke prevention strategies (cerebral embolic protection devices and antithrombotics) was evaluated. Cerebral embolic protection devices and tailored antithrombotic strategies have not yet demonstrated a definitive reduction in periprocedural stroke rates for patients undergoing transcatheter aortic valve implantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: